Nephron-sparing surgery of renal cell carcinoma with a normal opposite kidney: Long-term outcome in 180 patients

Citation
D. Filipas et al., Nephron-sparing surgery of renal cell carcinoma with a normal opposite kidney: Long-term outcome in 180 patients, UROLOGY, 56(3), 2000, pp. 387-392
Citations number
30
Categorie Soggetti
Urology & Nephrology
Journal title
UROLOGY
ISSN journal
00904295 → ACNP
Volume
56
Issue
3
Year of publication
2000
Pages
387 - 392
Database
ISI
SICI code
0090-4295(200009)56:3<387:NSORCC>2.0.ZU;2-X
Abstract
Objectives. To investigate the long-term outcome of an organ-saving approac h for renal cell carcinoma (RCC) with a normal opposite kidney (elective in dication). Methods. Since 1979, 180 patients have undergone nephron-sparing surgery at our institution for RCC in the presence of a normal contralateral kidney. The mean age was 56 years (range 23 to 85), and the mean follow-up was 4.7 years (maximum 14.8). Most of these tumors were found incidentally, with a mean tumor diameter on ultrasound of 3.3 cm (range 1.0 to 8.6). Results. The postoperative course was unremarkable in 173 patients. Postope rative bleeding was encountered in 4 patients and urinary extravasation in an additional 3 patients. No surgical reintervention was necessary. One hun dred seventy-five RCCs were pT1 and 5 were pT3a; 73 were grade 1, 100 grade 2, and 7 were grade 5. The mean tumor diameter (surgical specimen) was 3.2 cm (range 0.5 to 7). In 132 cases, the tumor was less than 4 cm and in 48 cases, greater than 4 cm. Three patients experienced local tumor recurrence (1.6%) during follow-up, and two others developed distant metastases. The 5-year tumor-specific survival rate was 98.0%. Conclusions. Nephron-sparing surgery for RCC under an elective indication i n selected patients offers excellent long-term survival and an acceptably l ow local tumor recurrence rate. These results support the concept of nephro n-sparing surgery in the presence of a normal contralateral kidney. UROLOGY 56: 387-392, 2000. (C) 2000, Elsevier Science Inc.